05 Aug FluGen brings in more funds from investors
FluGen has added $5.5 million to its coffers to prepare for the next round of studies on RedeeFlu, the nasal spray vaccine the Madison company has developed to protect against influenza.
CEO Paul Radspinner says the company is wrapping up its analysis of data from a study of nearly 100 healthy adults, designed to determine the safety of RedeeFlu and the appropriate dose. Results are not expected to be available until early 2018 but Radspinner said they were good enough to give the company confidence to move forward with a series of three studies next year.
Sorry, the comment form is closed at this time.